We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Otsuka Pharmaceutical and X-Chem announced that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
X-Chem will utilize its DNA-encoded library (DEX) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets.
Otsuka Pharmaceutical Co. announced an agreement with Neurovance, Inc. under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADH